Thrive Therapies Group
PrivateLast Round
Early Funding
Oct 22, 2026
Total Funding Raised
$7.7M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Thrive Therapies Group operates in Healthcare & Life Sciences and is based in Nashville, Tennessee. Its latest recorded funding round was an Early Funding round in October 2026.
Thrive Therapies Group is a healthcare technology company that provides clinician-led services and software tools to support the development and well-being of children with disabilities in school settings.
Sector
Healthcare & Life Sciences
Verticals
Vertical SaaS, Mental Health, Revenue Cycle, Compliance
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thrive Therapies Group Comparables
Compare Thrive Therapies Group with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Parallel Learning | 78% | |
| eLuma | 76% | |
| AbleSpace | 75% |
For institutional investors. Book with your work email.
Thrive Therapies Group Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 22, 2026 | ||||
| Seed Round | May 8, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Thrive Therapies Group Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Charter School Growth Fund | Early Funding, Seed |
| Activate Venture Partners | Early Funding |
| LiveOak Ventures | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 22, 2026
$8M raised, led by LiveOak Ventures.
- Jul 20, 2026
Open roles increased to 542, 6x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 23, 2026
Thrive Therapies Group receives $7.7M in funding led by LiveOak Ventures, with participation from Activate Venture Partners and Charter School Growth Fund, to expand into new markets, grow its clinical teams and develop Thrive Clinical.
For institutional investors. Book with your work email.
Thrive Therapies Group Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Thrive Therapies Group's valuation, stock price, and market status.
Is Thrive Therapies Group a public or private company?
Thrive Therapies Group is a private company.
What is the current stock price of Thrive Therapies Group?
Thrive Therapies Group is a private company, so its shares have no public market price. Caplight tracks Thrive Therapies Group's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thrive Therapies Group worth (valuation)?
Valuation information for Thrive Therapies Group is not publicly available.
Can I buy Thrive Therapies Group stock?
Thrive Therapies Group shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thrive Therapies Group's last funding round?
Thrive Therapies Group's most recent funding round was Early Funding on October 22, 2026.
Who are the main investors in Thrive Therapies Group?
Key investors in Thrive Therapies Group include LiveOak Ventures.
Will Thrive Therapies Group IPO soon?
No public IPO plans have been announced for Thrive Therapies Group.
How can I track Thrive Therapies Group secondary market activity?
Caplight tracks bids, offers, and trades in Thrive Therapies Group's shares on secondary markets.